E-viri
Recenzirano
Odprti dostop
-
SHLANSKY‐GOLDBERG, R. D.; MATSUMOTO, A. H.; BAUMBACH, G. A.; SIEGEL, J. B.; RAABE, R. D.; MURPHY, T. P.; DENG, C.; RAY DAWKINS, J.; MARDER, V. J.
Journal of thrombosis and haemostasis, June 2008, Letnik: 6, Številka: 6Journal Article
Background: Hemodialysis (HD) grafts often fail because of stenosis at the venous anastomosis and thrombotic occlusion. Percutaneous management relies on thrombolysis with plasminogen activators, mechanical removal of thrombus, and angioplasty of the stenotic lesion. Objectives: This report describes a phase I trial using Plasmin (Human) TAL 05‐00018, a direct‐acting fibrinolytic agent, to evaluate safety and, secondarily, to establish effective thrombolytic dosing. Patients/Methods: Six cohorts of five patients with acute HD graft occlusion documented by angiography were treated with escalating dosages of plasmin (1, 2, 4, 8, 12, and 24 mg) infused over 30 min via criss‐crossed pulse‐spray catheters within the graft. The primary efficacy endpoint was ≥50% thrombolysis, as determined by comparison of pre‐plasmin and 30‐min post‐plasmin fistulograms. Results: Of 31 subjects who received study drug (safety population), one withdrew and 30 completed the trial (evaluable for efficacy). There was no significant change in plasma α‐2 antiplasmin or fibrinogen concentration, major bleeding did not occur, and there were no deaths. Serious adverse events in four patients were not related to the study drug. There was a dose–response relationship for the primary efficacy endpoint, all five subjects receiving 24 mg achieving >75% lysis. Conclusions: This first phase I study of Plasmin (Human) TAL 05‐00018, infused into thrombosed HD grafts, documents safety at dosages of 1–24 mg and an effective thrombolytic dosage of 24 mg. The results establish a foundation for further clinical study of catheter‐based plasmin administration in thrombotic disorders.
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.